Enveric Biosciences Inc Stock Price, News & Analysis

Enveric Biosciences (NASDAQ: ENVB) has announced positive preclinical results for its lead drug candidate EB-003 in treating severe chronic depression. The drug demonstrated statistically significant improvements in the Open Space Forced Swim Test, a preclinical mouse model. At an oral dose of 30 mg/kg, EB-003 significantly reduced depression-like behavior within 30 minutes, showing comparable effects to Imipramine, an approved antidepressant.

The study confirmed the efficacy of the 30 mg/kg dose and revealed no adverse locomotor effects. Additionally, a 22-day daily dosing trial showed no adverse behavioral, physiological, or neurological effects, supporting its safety for long-term use. EB-003 is part of Enveric's EVM301 Series, designed to stimulate synaptic plasticity without hallucinogenic effects.

Enveric Biosciences (NASDAQ: ENVB) has filed a new provisional patent application for a family of molecules showing potential in treating neurodegenerative diseases. The molecules enhance brain-derived neurotrophic factor (BDNF) activity and target the BDNF/TrKB pathway, which supports neuroprotection and adult neurogenesis.

Initial testing revealed promising results, including promotion of neuronal development in cell-based assays. A prototype molecule demonstrated favorable pharmaceutical and pharmacokinetic characteristics, including effective oral delivery, brain penetration, and rapid plasma clearance, without showing 5HT2B receptor activation that could indicate cardiovascular risks.

The discovery could expand Enveric's market potential, targeting an estimated 50 million people worldwide affected by neurodegenerative diseases, including 7 million in the United States.

Enveric Biosciences (NASDAQ: ENVB) reported its Q4 and fiscal year 2024 results, highlighting progress in developing novel neuroplastogenic therapeutics. The company's lead candidate EB-003 demonstrated positive preclinical results, including oral bioavailability and significant brain exposure. The company secured multiple licensing deals, including agreements with Aries Science & Technology (up to $61M in milestones), MycoMedica Life Sciences (up to $62M in milestones), and Restoration Biologics (up to $82M in combined milestones).

Financial results showed a Q4 2024 net loss of $3.2 million ($4.83 per share), compared to a $3.4 million loss ($21.90 per share) in Q4 2023. Cash position stood at $2.2 million as of December 31, 2024. The company completed a $5 million public offering during the period.

Enveric Biosciences (NASDAQ: ENVB) announced its participation in BIO-Europe Spring®, taking place in Milan, Italy, March 17-19, 2025. The biotechnology company, focused on developing novel neuroplastogenic small-molecule therapeutics for anxiety, depression, and addiction disorders, will conduct one-on-one meetings with investors and potential partners during the event.

The company plans to showcase its business strategy, clinical development progress, recent achievements, and upcoming milestones. CEO Joseph Tucker highlighted their strategic approach to developing neuroplastogenic molecules, particularly EB-003, emphasizing their focus on eliminating or reducing hallucinatory effects common to N,N-Dimethyltryptamine (DMT), mescaline and related analogs as key to commercial success.

Enveric Biosciences (NASDAQ: ENVB) has announced a Request-For-Proposals (RFP) process for the license or sale of its PsyAI™ trademark portfolio in the US and Canada. The company has already received two expressions of interest, initiating an auction process that will remain open until August 31, 2025.

The PsyAI™ trademark was originally intended for software applications in medical research data analytics and machine learning. However, Enveric is now focusing on developing its lead compound EB-003, a potential first-in-class neuroplastogen for depression, anxiety, and addiction disorders.

The company sees significant potential value in the PsyAI™ mark, particularly in the growing AI healthcare market. According to cited research, the global AI market is projected to reach $757B by 2025, with the mental health AI segment expected to grow from $0.9B in 2023 to $14.9B by 2033.

Enveric Biosciences (NASDAQ: ENVB) has announced strategic updates through a CEO letter to shareholders. The company has repositioned to focus on developing EB-003, their lead non-hallucinogenic neuroplastogenic drug candidate for anxiety, depression, and addiction disorders. Recent data shows EB-003's ability to bind to the 5-HT2A receptor and induce neuroplasticity without significant hallucinatory effects.

The company completed several licensing agreements in 2024-2025, including partnerships with Aries Science & Technology, MycoMedica Life Sciences, and Restoration Biologics. Enveric recently secured new U.S. patents for their EVM301 series and unveiled the EVM401 Series of mescaline-inspired drug candidates.

Financially, Enveric completed a public offering raising approximately $5 million in gross proceeds after implementing a reverse stock split. The company is now preparing for EB-003's Investigational New Drug (IND) application and subsequent Phase 1 clinical trials.

Enveric Biosciences (NASDAQ: ENVB) has secured U.S. Patent No. 12,195,439 for its new EVM401 Series of mescaline derivative compounds. The patent, issued on January 14, 2025, covers 'Cl-Substituted Isopropylamine Fused Heterocyclic Mescaline Derivatives.'

Preliminary testing shows these compounds demonstrate unique brain receptor modulation patterns, potentially interacting with:

• α2A adrenergic receptor (ADRA2A) - helpful for opioid withdrawal and ADHD
• 5-HT2C receptor - target for neuropsychiatric diseases, substance use disorders, anxiety and depression
• Dopamine transporter (DAT) - important for substance use disorder treatment

While the company's main focus remains on the IND application for EB-003, this patent aims to expand their pipeline of non-hallucinogenic molecules for treating addiction and neuropsychiatric disorders.